NCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
Clinical Trials
4 trialsNCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT01061840 2022-03-15
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Gradalis, Inc.
Phase 1 Completed
NCT02574533 2017-09-27
Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma
Gradalis, Inc.
Phase 1 Completed